Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04645212 |
Recruitment Status :
Active, not recruiting
First Posted : November 27, 2020
Last Update Posted : February 14, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Wet Age-related Macular Degeneration Neovascular Age-related Macular Degeneration | Biological: ADVM-022 |
ADVM-022 (AAV.7m8-aflibercept) is a gene therapy product developed for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is a serious condition and the leading cause of blindness in the elderly. The available therapies for treating wet AMD require life-long intravitreal (IVT) injections every 4-12 weeks to maintain efficacy. A one-time IVT administration of ADVM-022 has the potential to treat wet AMD by providing durable expression of therapeutic levels of intraocular anti-VEGF protein (aflibercept) and maintaining the vision of patients. ADVM-022 is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with wet AMD receiving anti-VEGF therapy in clinical practice.
ADVM-022-07 is an observational long-term extension (OPTIC-EXT) study assessing safety and efficacy of ADVM-022 gene therapy product, in subjects with neovascular, or exudative (wet), age-related macular degeneration (nAMD).
To evaluate potential long-term outcomes of ADVM-022, the OPTIC-EXT will follow subjects previously treated in the OPTIC parent study (Clinical Protocol No. ADVM-022-01 [OPTIC] (NCT03748784)). Subjects will roll over from the OPTIC parent study and will be followed for 3 additional years, following completion of the preceding 2-year assessment period in the OPTIC parent study. There is no investigational treatment administered in this study.
Study Type : | Observational |
Actual Enrollment : | 23 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | A Long-term Study of ADVM-022 in Neovascular (Wet) AMD - OPTIC Extension |
Actual Study Start Date : | December 14, 2020 |
Estimated Primary Completion Date : | June 2025 |
Estimated Study Completion Date : | June 2025 |
Group/Cohort | Intervention/treatment |
---|---|
1
Subjects with wet AMD who received any dose of ADVM-022 in a prior clinical study.
|
Biological: ADVM-022
Long term follow-up of subjects that received ADVM-022
Other Name: AAV.7m8-aflibercept |
- Type, severity and incidence of ocular and systemic adverse events (AEs). [ Time Frame: 156 weeks ]Type, severity and incidence of ocular and systemic adverse events
- Change in best corrected visual acuity (BCVA) from baseline, over time [ Time Frame: 156 weeks ]Change in best corrected visual acuity (BCVA) from baseline, over time
- Mean change in central subfield thickness (CST) and macular volume from baseline, over time [ Time Frame: 156 weeks ]Mean change in central subfield thickness (CST) and macular volume from baseline, over time
- Percentage of subjects requiring supplemental aflibercept over time [ Time Frame: 156 weeks ]Percentage of subjects requiring supplemental aflibercept over time
- Mean number of supplemental aflibercept injections over time [ Time Frame: 156 weeks ]Mean number of supplemental aflibercept injections over time
- Percentage of subjects without intraretinal fluid (IRF) by spectral domain optical coherence tomography (SD-OCT), over time [ Time Frame: 156 weeks ]Percentage of subjects without intraretinal fluid (IRF) by spectral domain optical coherence tomography (SD-OCT), over time
- Percentage of subjects without subretinal fluid (SRF) by SD-OCT over time [ Time Frame: 156 weeks ]Percentage of subjects without subretinal fluid (SRF) by SD-OCT over time
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 50 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
- Subjects who received ADVM-022 at any dose in the OPTIC study
- Up to 30 subjects from all cohorts of OPTIC
Inclusion Criteria:
- Subjects who received a single dose of ADVM-022 at any dose in the OPTIC study
- Willing and able to provide informed consent
Exclusion Criteria:
- None
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04645212
United States, California | |
Adverum Clinical Site | |
Bakersfield, California, United States, 93309 | |
Adverum Clinical Site | |
Beverly Hills, California, United States, 90211 | |
United States, Colorado | |
Adverum Clinical Site | |
Lakewood, Colorado, United States, 80228 | |
United States, Florida | |
Adverum Clinical Site | |
Deerfield Beach, Florida, United States, 33064 | |
United States, Nevada | |
Adverum Clinical Site | |
Reno, Nevada, United States, 89502 | |
United States, Pennsylvania | |
Adverum Clinical Site | |
Philadelphia, Pennsylvania, United States, 19107 | |
United States, Tennessee | |
Adverum Clinical Site | |
Nashville, Tennessee, United States, 37203 | |
United States, Texas | |
Adverum Clinical Site | |
Bellaire, Texas, United States, 77401 | |
Adverum Clinical Site | |
The Woodlands, Texas, United States, 77384 |
Study Director: | OPTIC Medical Monitor | Adverum Biotechnologies, Inc. |
Responsible Party: | Adverum Biotechnologies, Inc. |
ClinicalTrials.gov Identifier: | NCT04645212 |
Other Study ID Numbers: |
ADVM-022-07 |
First Posted: | November 27, 2020 Key Record Dates |
Last Update Posted: | February 14, 2023 |
Last Verified: | February 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Choroidal Neovascularization ADVM-022 OPTIC Study CNV ADVM-022-01 ADVM-022-07 AAV.7m8 Anti-VEGF therapy Blindness Gene therapy Aflibercept (Eylea) Age-Related Macular Degeneration Wet Macular Degeneration |
Retinal Degeneration Retinal Diseases Eye Diseases AAV Vector Adverum wAMD AMD wet AMD nAMD OPTIC Extension OPTIC-EXT Long-term Follow Up Long-term Extension |
Macular Degeneration Retinal Degeneration Retinal Diseases Eye Diseases Aflibercept Angiogenesis Inhibitors |
Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors Antineoplastic Agents |